February 9: Medical Device Breakfast Series | Company Valuation for M&A
The valuation of a medical device company for merger or acquisition is not an exact science. Some of the many variables to be taken into consideration include the company’s management, market share, prospects for growth, and potential market size. Tangible and intangible assets and financial track record will be evaluated, as well as the company's reputation in the business community. The motivation and goals of key players also come into play, and current market conditions and timing are factors. A panel of industry veterans will explore the valuation process for medical device companies, discuss case studies and provide practical answers to help you increase your company’s valuation. Detailed Information

February 11, 2010: BayBio NEST | A Sweet Deal: How to Attract Investors
Venture Capitalists and Angel Investors are still looking for good prospects despite the economic downturn. Understanding what they want, at what stage they want to invest and the difference between them can help start-ups form a successful relationship with investors. Join BayBioNEST for the first of our 2010 Venture Spotlight Series events and learn how best to attract investors and secure a sweet deal. In Menlo Park. Detailed Information

February 24: CEO & CFO Roundtable: What’s Ahead for the Biotech IPOs
The latest biotech headlines are contradictory at best: some hail fresh signs that biotech IPOs are beginning a long-awaited revival and declare that IPO activity in the biotech arena is starting to heat up, others are more cautious in their observations, stating that IPO markets have become more challenging and Mergers and Acquisitions – not IPOs - are the most viable exit strategy for most companies. Join BayBio in an interactive session to learn firsthand from “bulls” and “bears” of their thoughts, war stories & insights. Detailed Information

February 24: SBIR-STTR Grant Writing Workshop
You may have been a master of grant writing, but things are about to change! The NIH is unrolling a shortened and restructured format for grants starting in 2010. The research plan is fully restructured and reflects new evaluation criteria. Even people who have written grants in the past are going to need to “relearn” the process. Join us for an interactive workshop on grant writing basics and pitfalls. This event will cover general submissions and writing strategies, with a special focus on NIH SBIRs new submission format. In Palo Alto. Detailed Information

February 25: Therapeutic Breakfast | Clinical Trials Abroad: Options for Smaller Companies with Limited Funds
With current financial pressures mounting and global clinical trial opportunities expanding, more and more life sciences companies are exploring opportunities to run clinical trials abroad. Though potential savings in time and money can be very significant, outsourcing for efficiency comes with serious challenges for any company especially for smaller organizations. Industry experts will discuss approaches for dealing with cultural and linguistic differences techniques to ensure that the speed of trial conduct comes together with reliable data and creating optimized programs to fit specific budgets. In Redwood City. Detailed Information

March 11, 2010: BayBio NEST | Heart Matters: Investments in Heart Disease
Heart disease is the leading cause of death worldwide, killing one person every 34 seconds in the US alone. In 2009, the estimated cost of cardiovascular disease in the United States was $475.3 billion according to the American Heart Association and the NHLBI. However, mortality rates have decreased due to improved prevention, diagnosis and treatment. This panel will discuss promising new areas of research and developing trends that are attracting funds. In Menlo Park. Detailed Information

March 17, 2010: BayBio NEST | 7th Annual Life Sciences Investor and Entrepreneur Roundtables
The Entrepreneur and Investor Roundtables event is a unique event designed to facilitate introductions, dialogs and establish connections between life science entrepreneurs and investors. This event provides early stage companies with an accessible first step into the capital markets while providing investors a first look at intriguing innovations. The Entrepreneur and Investor Roundtables event is well known for its iconic ‘speed-dating’ format. Each year, VC firms and Angel Investors listen to brief pitches from dozens of biotech entrepreneurs. In Palo Alto. Detailed Information

March 23: BioFacilities | Industry Knowledge for the Non-Scientist
Further your understanding of the unique real estate and facility requirements of the dynamic and highly regulated biotech and pharmaceutical industries. Be more strategic in the development and implementation of economic development strategies targeting this growth industry by understanding the language of the industry’s built environment needs. Advance your knowledge of key performance and specific uses driving the cost of developing and operating these technical facilities. Enhance your ability to provide consultative representation to property owners and tenants. Learn from well-regarded Biotech Primer instructors that have the skill and hands-on experience to teach individuals drawing from a wide variety of professions in an engaging environment. In Menlo Park.Detailed Information

March 25, 2010: Therapeutic Breakfast Series | Establishing and Successfully Managing Strategic Alliances
The current economic climate and market pressures are forcing a change in strategy for both established and emerging life sciences companies. The IPO market is gone. The VC funding is dry. Companies, seeking to deliver new treatments and cures, are forming alliances with larger organizations at a faster pace. Some are even saying that we are witnessing a fundamental change, where success will depend on a company's capacity to manage multiple relationships as part of a larger collaborative network. To be successful, companies will need to effectively develop and manage alliances, they must also learn how to remain relevant to their partners and be flexible enough to evolve with changes in the partner's strategy. Join us for a panel of expert Alliance executives to learn how to become "alliance capable" and thrive through collaborations in the new environment. In Redwood City. Detailed Information

April 7, 2010: BayBio2010 | Life Science Innovation: Drivers and Barriers
BayBio2010 is a one-day conference focusing on Northern California's strength in life sciences innovation. This conference will examine the fundamental questions of who pays for biotech innovation and why in this unprecedented environment. It will focus on how the current financing environment and new sources of capital affect business models, development and commercialization strategies. In doing so, BayBio2010 will consider government initiatives, such as healthcare reform, clean energy legislation and American Recovery and Reinvestment (ARRA) funding, and effects of these programs on therapeutic, diagnostic and clean tech companies. Additionally, the conference will review new trends in public markets, venture investment, M&A and partnering with larger companies and how they affect the life sciences research and development process. Finally, BayBio2010 will investigate how changing consumer behavior and resulting economic realities factor into biotech company strategies. Located at the Hyatt Regency San Francisco Airport: 1333 Bayshore Highway Burlingame, CA.Detailed Information

April 29, 2010: BayBio NEST | Technology Showcase at SRI International
The 2010 Technology Showcase at SRI International provides a sneak peak at the science within the organization often before it is published or patented. Network with scientists and entrepreneurs behind the work. SRI's Biosciences Division provides target identification, lead discovery/optimization, vaccine development, neuropharmacology research in sleep and pain, microbiology, efficacy models, comprehensive toxicology, PK/ADME, formulation, analytical chemistry, cGMP manufacturing, QA, IND preparation and government grant teaming services. In Menlo Park. Detailed Information

May 12: BayBio Executive Series | Managing the Board
The Board of Directors should be one of the strongest assets a company possesses. It is the one asset that can be both long term and strategic as well as short term and operational. The Board of Directors can function to provide leadership, to be an advisor, to be a sounding board and to even help with implementation in certain circumstances. Within this scope of potential involvement, the board members need to be strategically managed like any other asset. This hard task falls on the CEO, who is charged with maintaining a vibrant and productive board, strategic recruitment, resolving conflicts of interest, aligning visions of the board and executive team, executing effective communications, evaluating board member performance to ensure each director is providing necessary value to the company, and dealing with disruptive or inadequate board members. Attending life sciences CEOs and CFOs will be able to gather and share unique personal insights and recommendations of how to work most effectively with a Board of Directors in both public and private company settings. Open to C Suite Executives of Life Sciences Companies Only. This event is by invitation only and the invitation is not transferrable. Detailed Information

May 19: California Life Sciences Day
Join leaders in biotechnology, medical devices, pharmaceuticals and biomedical research in Sacramento on Wednesday, May 19, 2010 to build support for the issues that matter most to California's medical innovators. Attendees will participate in face-to-face meetings with legislators and state government officials, enjoy a networking luncheon and join legislators and their staffs at a closing reception. By joining forces and speaking with one voice, we can successfully advocate the collective economic impact and human value of our work. In Sacramento. Detailed Information